Wellington Management Group LLP Acquires 736,709 Shares of Immatics (NASDAQ:IMTX)

Wellington Management Group LLP boosted its holdings in Immatics (NASDAQ:IMTX - Free Report) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,417,892 shares of the company's stock after purchasing an additional 736,709 shares during the period. Wellington Management Group LLP owned about 8.73% of Immatics worth $74,071,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. lifted its stake in shares of Immatics by 17.5% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,354,711 shares of the company's stock worth $15,457,000 after buying an additional 202,255 shares during the last quarter. Schroder Investment Management Group increased its holdings in Immatics by 52.6% in the 4th quarter. Schroder Investment Management Group now owns 427,994 shares of the company's stock valued at $2,953,000 after buying an additional 147,547 shares during the period. abrdn plc increased its holdings in Immatics by 49.2% in the 4th quarter. abrdn plc now owns 347,379 shares of the company's stock valued at $2,470,000 after buying an additional 114,479 shares during the period. Platinum Investment Management Ltd. increased its holdings in Immatics by 53.1% in the 4th quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company's stock valued at $2,216,000 after buying an additional 108,108 shares during the period. Finally, State Street Corp grew its holdings in shares of Immatics by 11.2% during the 3rd quarter. State Street Corp now owns 225,202 shares of the company's stock valued at $2,570,000 after purchasing an additional 22,710 shares during the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.

Immatics Stock Down 5.4 %

IMTX traded down $0.22 during trading on Thursday, hitting $3.82. 124,078 shares of the company traded hands, compared to its average volume of 646,923. The firm has a market cap of $464.44 million, a P/E ratio of -5.80 and a beta of 0.85. The stock's fifty day moving average is $4.65 and its 200 day moving average is $6.91. Immatics has a one year low of $3.30 and a one year high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.51. The firm had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. On average, equities research analysts forecast that Immatics will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $16.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.